ReviewIntensive care medicine2014
Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?
Review in Intensive care medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03090334 (A B-D-Glucan Driven Antifungal Stewardship Approach to Manage Empirical Therapy in Patients at Very High Risk for Invasive Candidiasis), which is not on this map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A B-D-Glucan Driven Antifungal Stewardship Approach to Manage Empirical Therapy in Patients at Very High Risk for Invasive Candidiasis: a Randomized Controlled Trial
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 136 citations in OpenAlex.
- Candida spondylodiscitis: a systematic review and meta-analysis of seventy two studies.International orthopaedics · 2024Pooled it
- Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial.Intensive care medicine · 2017Trial
- Lectin-Fc(IgG2a) fusion proteins binding to the cell wall ofMicrobiology spectrum · 2026Article
- High azole resistance among non-albicans Candida species causing vulvovaginal candidiasis in Western Uganda: a cross-sectional study.Infection · 2026Article
- Potential Antifungal Activity of Retinoids Against Non-Microorganisms · 2026Article
- A mitochondria-targeted aggregation-induced emission photosensitizer for eradicationSmart molecules : open access · 2025Article
- Biofilm-Associated Candidiasis: Pathogenesis, Prevalence, Challenges and Therapeutic Options.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Phenotypic and Genotypic Characterization of Resistance and Virulence Markers inJournal of fungi (Basel, Switzerland) · 2024Article
- Prevalence of Oropharyngeal Candidiasis and distribution ofResearch square · 2024Article
- Antifungal and antibiofilm effects of probioticFrontiers in cellular and infection microbiology · 2024Article
- Clinic-mycological spectrum ofCurrent medical mycology · 2023Article
- Design, Synthesis, and Biological Evaluation ofInternational journal of molecular sciences · 2023Article
- Toward more potent imidazopyridine inhibitors of Candida albicans Bdf1: Modeling the role of structural waters in selective ligand binding.Journal of computational chemistry · 2022Article
- Lectins ConA and ConM extracted from Canavalia ensiformis (L.) DC and Canavalia rosea (Sw.) DC inhibit planktonic Candida albicans and Candida tropicalis.Archives of microbiology · 2022Article
- Two New Compounds Containing Pyridinone or Triazine Heterocycles Have Antifungal Properties againstAntibiotics (Basel, Switzerland) · 2022Article
- The emerging threat antifungal-resistantFrontiers in fungal biology · 2022Review
- Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?Infection · 2021Review
- Selenium nanoparticles fromSaudi journal of biological sciences · 2021Article
- Phytochemical characterization and inhibition of Candida sp. by the essential oil of Baccharis trimera (Less.) DC.Archives of microbiology · 2021Article
- Detection of Intrinsically Resistant Candida in Mixed Samples by MALDI TOF-MS and a Modified Naïve Bayesian Classifier.Molecules (Basel, Switzerland) · 2021Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current increases in antifungal drug resistance in Candida spp. and clinical treatment failures are of concern, as invasive candidiasis is a significant cause of mortality in intensive care units (ICUs). This trend reflects the large and expanding use of newer broad-spectrum antifungal agents, such as triazoles and echinocandins. In this review, we firstly present an overview of the mechanisms of action of the drugs and of resistance in pathogenic yeasts, subsequently focusing on recent changes in the epidemiology of antifungal resistance in ICU. Then, we emphasize the clinical impacts of these current trends. The emergence of clinical treatment failures due to resistant isolates is described. We also consider the clinical usefulness of recent advances in the interpretation of antifungal susceptibility testing and in molecular detection of the mutations underlying acquired resistance. We pay particular attention to practical issues relating to ICU patient management, taking into account the growing threat of antifungal drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.